摘要
目的观察药物干预的糖尿病肾病(DN)患者尿单核细胞趋化蛋白-1(MCP-1)和尿白蛋白排泄率(UAER)的变化。方法36例患者随机分成3组,苯那普利10mg/d组,缬沙坦80mg/d组,苯那普利与缬沙坦联用组,随机分组后的0周、8周、12周进行MCP-1和UAER的检测的,分别计算其治疗前后的下降率。结果患者的24小时尿液MCP-1与UAER结果存在明显直线相关性(r=0.549、P<0.05)。而治疗12周后,苯那普利组较缬沙坦组每分钟尿MCP-1的降低率有显著性差异(0.182±0.065VS0.231±0.057,P<0.05),而UAER未见显著性差异(0150±0.045VS0.183±0.057,P>0.05)。结论尿MCP-1作为微血管病变的特异性和敏感性指标有一定意义。
Objective Aim To study the relationship between urinary monocyte chemoattractant protein-1(MCP-1)and urinary albumin excretion rate(UAER)in patiets with diabetic nephopathy(DN);intervened by drug.Methods 36 patients with DN were divided intO 3 groups by random.Group 1was treated Wlth Benazepril(10mg/d).Group 2was treated with Valsartant(80mg/d).And group 3 was treated with combination of two drug as above.Before treatment and after 8,12weeks of DOSt-treament MCP-1 levels were measured by ELISA and UAER Were measured by radioimmunoassay,as well as calculate decent rate.Results There was posltive correlation between.levels and UAER in DN(r=0.549,p<0.05).was signiticanthigher in Group l compared with Group2(0.182±0.065vs0.231±0.057,p<0.05);There was no significant different in UAER between thegrop l and 2.Conclusion Urinary MCP-1 maybe a sensltive and specificbiomarker to refect the dysfunction of nephridium in patient,with DN.
出处
《医学检验与临床》
2008年第2期18-19,共2页
Medical Laboratory Science and Clinics
